NAMPT and liver cancer: reported that inhibition of NAMPT reduced PD-L1 expression and that NAMPT deficiency impaired the therapeutic effect of PD-L1 checkpoint blockade on liver cancer in mice, which was further validated in melanoma samples obtained from patients (26).